OTLK Stock Analysis: Buy, Sell, or Hold?
OTLK - Outlook Therapeutics, Inc. Common Stock
$1.64
-0.06 (-3.53%)
▼
5d:
+4.46%
30d:
+429.2%
90d:
+727.86%
WAIT
LOW Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When OTLK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: OTLK is 17.1% above its trading range ($1.40). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: OTLK is 17.1% above its trading range ($1.40). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: OTLK is currently trading at $1.64, which is considered extended relative to its 30-day fair value range of $0.42 to $1.40.
Technical Outlook: Technically, OTLK is in a uptrend. The price is approaching resistance at $0.94. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: OTLK has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $5.50 (+223.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, OTLK is in a uptrend. The price is approaching resistance at $0.94. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: OTLK has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $5.50 (+223.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.42 -
$1.40
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
47.4%
All Signals
- BEARISH: Price significantly overextended (+17.1% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.5%)
- BULLISH: Trading 223.5% below Wall St target ($5.50)
- WARNING: Recommendation downgraded due to 17.1% overvaluation
Trading Range Analysis
30-Day Trading Range
$0.42 -
$1.40
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.40
Resistance Level
$0.94
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.73
Wall Street Target
$5.50
(+223.5%)
Revenue Growth (YoY)
658.3%
Share & Embed Analysis
Last updated: June 24, 2026 3:44 PM ET
Data refreshes hourly during market hours. Next update: 4:44 PM
Data refreshes hourly during market hours. Next update: 4:44 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OTLK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 57 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 58 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 56 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
